Requested symbol wasn't found

U.S. Markets close in 4 hrs 53 mins
Loading...
Loading...
  • American City Business Journals2 months ago

    ​FDA approves Cambridge-based Vericel's knee cartilage repair product

    Shares of Cambridge-based Vericel surged late Tuesday after the FDA approved a treatment for knee cartilage repair that involves harvesting a patient’s own cells. The FDA said it had approved Vericel's Maci, a product that collects and expands a patient’s cells — called autologous cells — then places them onto a collagen membrane that is implanted over the area where tissue was removed. Vericel has two other FDA-approved products, skin graft treatment Epicel and another knee cartilage repair product called Carticel.

  • Marketwired2 years ago

    Aastrom Biosciences Changes Name to Vericel Corporation

    Aastrom Biosciences, Inc. , a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the change of its corporate name to ...

  • Zacks Small Cap Research2 years ago

    Aastrom Fundamentals Continue To Improve

    We rates shares of Aastrom Biosciences, Inc. (ASTM) a 'Buy' and are adjusting our target to $6.50 per share. Based on industry-average multiples, we see Aastrom's stock doubling in 2015. On November 13, 2014, Aastrom Biosciences reported financial results for the quarter of 2014 ending September 30, 2014. Results in the quarter included a full quarter of operations for the recently acquired Cell Therapy and Regenerative Medicine ("CTRM") business from Sanofi (SNY), previously known as Genzyme Biosurgery Aps.